



Eisai Co., Ltd.

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 , Japan

Phone: 03- 3817-5120

Fax: 03- 3811-3077

Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their f

<Notes to Editors>

> **GLIADEL® Wafer**

GLIADEL® Wafer is approved by the U.S. FDA for the treatment of patients with newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, as well as for the treatment of patients with glioblastoma multiforme as an adjunct to surgery. In the U.S., since its launch in 1997, over 20,000 procedures have been performed with GLIADEL® Wafer.

GLIADEL® Wafer is a dime-sized wafer (1 mm thick and 14.5 mm in diameter) that contains 7.7 mg of carmustine. Up to eight wafers are implanted in the cavity created when a tumor is removed during surgery and the wafers deliver carmustine, a type of chemotherapy.

> **About glioma**

Glioma is a tumor that arises from glial cell in the brain and is malignant with poor prognosis in most cases. Glioma consists of 30% of primary brain tumor and is classified into several types according to the cell form of the tumor. The most common type is astrocytoma, which is classified into four grades (grade I to IV) according to the grade of malignancy. Grade IV astrocytoma is called glioblastoma, which has the highest degree of malignancy and also has an extremely poor prognosis. Although surgical operations (craniotomy) are performed as standard treatment for glioma, it is quite difficult to remove the tumor completely and radiation therapy and/or chemotherapy are given adjunctively in most cases.

> **About Nobelpharma, Co., Ltd.**

To develop the drugs of highly unmet medical needs to bring them to patients who need them most as a corporate mission, Nobelpharma, Co., Ltd. was established in 2003. Nobelpharma contributes to medical care, being deeply committed to research and development of drugs of highly unmet medical needs that include orphan drugs, drugs used in off-label, and drugs for pediatric use.

In 2008, three new drugs developed by Nobelpharma which are Nobelzin® capsules for the treatment of Wilson's disease, Lunabell® compound tablets for the treatment of dysmenorrhea associated with endometriosis, and Nobelbar® Intravenous Phenobarbital for the treatment of neonatal convulsion and status epilepticus successively received approval from MHLW.

814612 medical